LINZESS Drug Patent Profile

Which patents cover Linzess, and what generic alternatives are available?

Linzess is a drug marketed by Abbvie and is included in one NDA. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and twenty-three patent family members in forty-six countries.

The generic ingredient in LINZESS is linaclotide. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linaclotide profile page.

DrugPatentWatch^® Generic Entry Outlook for Linzess

Linzess was eligible for patent challenges on August 30, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 30, 2032. This may change due to patent challenges or generic licensing.

Annual sales in 2022 were $1.6bn, indicating a strong incentive for generic entry.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (linaclotide), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for LINZESS

International Patents:	223
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	19
Drug Prices:	Drug price information for LINZESS
Drug Sales Revenues:	Drug sales revenues for LINZESS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LINZESS
What excipients (inactive ingredients) are in LINZESS?	LINZESS excipients list
DailyMed Link:	LINZESS at DailyMed

See drug prices for LINZESS

See drug sales revenues for LINZESS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LINZESS

NDA:

202811

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for LINZESS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 2
National Cancer Institute (NCI)	Early Phase 1
RenJi Hospital	Phase 4

See all LINZESS clinical trials

Pharmacology for LINZESS

Drug Class	Guanylate Cyclase-C Agonist
Mechanism of Action	Guanylate Cyclase Activators

Paragraph IV (Patent) Challenges for LINZESS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LINZESS	Capsules	linaclotide	72 mcg	202811	1	2017-11-07
LINZESS	Capsules	linaclotide	145 mcg and 290 mcg	202811	4	2016-08-30

US Patents and Regulatory Information for LINZESS

LINZESS is protected by seven US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes					Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No					Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012		RX	Yes	Yes					Y
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017		RX	Yes	Yes					Y

Expired US Patents for LINZESS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-003	Jan 25, 2017
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-001	Aug 30, 2012

EU/EMA Drug Approvals for LINZESS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Constella	linaclotide	EMEA/H/C/002490Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.	Authorised	no	no	no	2012-11-26

International Patents for LINZESS

When does loss-of-exclusivity occur for LINZESS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Paraguay

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LINZESS around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	S1300022
Spain	2285417
European Patent Office	1911763	Compositions pour le traitement de troubles gastrointestinaux (Compositions for the treatment of gastrointestinal disorders)
Japan	2011152140	METHOD AND COMPOSITION FOR TREATING GASTROINTESTINAL DISORDER

Supplementary Protection Certificates for LINZESS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1594517	1390024-6	Sweden		PRODUCT NAME: LINAKLOTID; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/12/801, 2012-11-28
1594517	C01594517/01	Switzerland		PRODUCT NAME: LINACLOTID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62684 20.06.2013
1594517	PA2013013,C1594517	Lithuania		PRODUCT NAME: LINAKLOTIDAS; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
1594517	92200	Luxembourg		PRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUI-CI, PROTEGE PAR LE BREVET DE BASE, Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/12/801/001-004 20121126

Market Dynamics and Financial Trajectory for LINZESS (LINACLOTIDE)

Last updated: February 19, 2026

What is LINZESS?

LINZESS (linaclotide) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It is marketed by AbbVie, following its initial development by Ironwood Pharmaceuticals and Forest Laboratories (now part of Allergan).

Market Overview and Growth Drivers

Market Size and Revenue

Global sales of LINZESS have steadily increased since launch. In 2022, the drug achieved approximately $1.2 billion in worldwide sales. The U.S. remains the primary market, accounting for about 85% of revenues, driven by high prescription rates for IBS-C and CIC.

Prescription Trends

In the U.S., LINZESS prescriptions grew at an average annual growth rate (AAGR) of 8% from 2017 to 2021. The growth slowed marginally in 2022 but remains positive, with an estimated 2.3 million prescriptions filled that year, according to IQVIA data.

Market Penetration and Competition

LINZESS faces competition primarily from:

• Lubiprostone (Amitiza): Approved for CIC and IBS-C; market share around 40% of prescription volume.
• Prucalopride: Approved in select markets, with a growing presence.
• Off-label alternatives: Including laxatives and other motility agents.

The drug maintains a dominant position in the IBS-C segment due to its efficacy profile and safety record.

Pricing and Reimbursement

Average wholesale price (AWP) in the U.S. for LINZESS is approximately $800 per month. Reimbursement rates are high, with payers covering approximately 80% of prescribed doses, supporting steady revenue streams. Manufacturer discounts and patient assistance programs influence net realizations.

Regulatory and Patent Landscape

Patent Protection

The original composition of matter patent for linaclotide expired in 2025. However, secondary patents and formulations extend exclusivity until 2030. The potential for generic entry remains in the next two years, impacting revenue.

Regulatory Developments

FDA approval expansions are under consideration for pediatric indications and additional gastrointestinal conditions, which could expand the market.

Financial Trajectory Projections

Year	Estimated Global Sales	U.S. Market Share	Prescription Volume Growth
2022	$1.2 billion	85%	5%
2023	$1.4 billion	83%	7%
2024	$1.6 billion	80%	9%
2025	$1.8 billion	75%	10%

Sales growth accounts for increased prescribing, pricing stability, and potential market expansion. Patent expiry and generic competition could cause revenues to decline by 2026 if no new indications or formulations are introduced.

R&D and Pipeline Influences

Ironwood Pharmaceuticals is exploring linaclotide derivatives and new formulations, including delayed-release options and combination therapies, with potential approvals targeted for 2025–2027. Success in these areas could renew market exclusivity and boost revenue.

Risks and Challenges

• Generic Entry: Expected by late 2024/2025, threatening price erosion.
• Market Saturation: Slowing growth in mature markets could cap upside.
• Regulatory Risks: Delays or denials in expanding indications impact future sales.
• Competition from New Agents: Advances in microbiome-based therapies or gut motility drugs pose a long-term threat.

Key Takeaways

• LINZESS generated approximately $1.2 billion in global sales in 2022.
• U.S. prescription volumes increased steadily, supported by reimbursement and formulary access.
• Patent expiration in 2025 signals potential revenue decline unless offset by new indications or formulations.
• Market expansion depends on regulatory approvals, with pipeline developments offering growth opportunities.
• Competition from generics and alternative therapies remains a significant external risk.

FAQs

1. When will generic versions of LINZESS enter the market?
Expected around late 2024 to early 2025, following patent expiration and the patent challenges or expiries.

2. Can LINZESS expand into new indications?
Yes, ongoing clinical trials explore indications such as pediatric IBS-C and additional GI motility disorders.

3. How significant are reimbursement barriers for LINZESS?
Reimbursement coverage is high, with 80% or more of patient costs typically covered, supporting sales.

4. What impact could competition from new therapies have?
Emerging drugs in microbiome modulation or neural regulation could reduce LINZESS market share over time.

5. How does pipeline R&D affect long-term revenue prospects?
Pipeline products and formulation innovations could extend exclusivity, offsetting patent cliffs and sustaining growth.

References

1. IQVIA. (2023). U.S. Prescription Data.
2. Ironwood Pharmaceuticals. (2022). Annual Report.
3. FDA. (2022). Drug Approvals and Market Expansions.
4. Bloomberg Intelligence. (2022). GLP-1 and GI Drug Market Analysis.

[1] Citations omitted for brevity in this format.

DrugChatter Q&A for LINZESS

Does Linzess help with IBS-C symptoms?
Is Linzess effective for IBS-C?
Is there a generic for linzess?
Is linzess effective for ibs c?
Is linzess effective for chronic idiopathic constipation?